finalized. The committee wishes to communicate to all stakeholders the following key points.
1. The professional society operator and institutional requirements are intended to provide guidance and support for a large number of centers throughout the US with a rational balance between patient access to TAVR therapy and quality outcomes. Questions regarding patient access to TAVR are complex and multifactorial and mirror similar barriers to access that exist in medical care in the US. Primary care providers play a critical role in facilitating access to TAVR with recognition and diagnosis of valvular heart disease leading to referral for specialized care.
2. This document does not recommend that sites failing to meet all requirements should close their TAVR-surgical aortic valve repair (SAVR) programs. Rather, the committee recommends that all sites review their quarterly outcome reports and assess if they are within national benchmarks of acceptable quality of care. An accreditation process is one means to help ensure quality and also provide external review of programs. sequence of expanded indications for TAVR is that some programs offering both SAVR and TAVR will see SAVR volume fall below the required threshold. If this occurs, it is not the intent of the committee to have sites maintain SAVR volume by deviating from a shared decision-making (SDM) process with patients and heart team guidance. The committee recommends that all sites should assess the quality of their SAVR programs using site performance metrics from STS and maintain a two-star to three-star rating.
Many United State regions have a low population density with
long distances to tertiary medical care. TAVR sites have opened in many of these regions, and it is important that they remain active if they can document acceptable quality even if they should fall below volume thresholds to maintain patient access to care. 6 . This document presents the types and details of currently available outcome metrics that enable an objective assessment of site performance. Importantly, additional metrics are under development to make this a more comprehensive assessment, including alive and well at 1 year. The incorporation of these additional metrics will diminish the need to rely on raw volume numbers. Cardiomyopathy Questionnaire (KCCQ) score. The composite will reflect both the team's capabilities in selecting patients who stand to benefit most from TAVR and in not recommending TAVR when the risk-benefit ratio is unfavorable or futile.
c. All sites must submit accurate and complete data to ensure accurate quality assessment and to achieve the goals of these standards.
7. An additional important consideration is that transcatheter devices continue to evolve. There may not be a class effect with TAVR in terms of complication patterns such that device-specific data will be necessary to study outcomes.
The Duke Clinical Research Institute has performed a preliminary
analysis of the most recent STS/ACC TVT Registry data that show a clinically meaningful association of higher mortality and other major complications with site annual volume below the recommended threshold of 50 procedures/year. Further analysis of these data is needed to confirm these preliminary findings and to more fully understand the factors associated with these worse outcomes. This further analysis is also needed to assess why some low-volume sites have acceptable outcomes and others do not, and to understand if these sites improve over time. The committee feels that elimination of annual procedure volume requirements would result in a possibility of increased TAVR riskadjusted mortality and major complications in the US despite five consecutive years of improving outcomes.
a. The assessment of site performance with low annual volumes is a major statistical challenge. Low annual volumes of TAVR, as well as SAVR, require an increased scrutiny of quality assessment results because of wider confidence bands and greater variability of outcomes. New analytic methods need to be applied to achieve valid assessment of low-volume sites' performance. Using multiyear data from sites with low annual volumes is one approach to addressing this challenge.
1 | INTRODUCTION
| Background
The goal of the writing committee was to provide a quality framework for any center providing TAVR as a treatment option for aortic valve disease in the US.
While this document specifically addresses TAVR requirements, it should be placed in a larger context and specifically address the broader goal of optimizing the care of all patients with severe aortic valve disease. Since publication of the original document in 2012, TAVR indications have been extended into groups of patients who are eligible for SAVR at intermediate to high risk; TAVR has also become an alternative to reoperation for those with severe bioprosthetic aortic valve degeneration. [2] [3] [4] Programs are now evaluating a broad spectrum of patients who may be appropriate for either form of valve replacement (i.e., TAVR and SAVR). The approval of a TAVR valve for a specific STS SAVR risk population does not necessarily mean that TAVR should be the chosen procedure for any particular patient in that population.
| What is new in the 2018 TAVR operator and institutional requirements?
The writing committee recognizes that adequate TAVR outcomes data are now available, permitting an evolution from an exclusively prerequisite skills-based set of recommendations to an integration of actual TAVR quality and experience as the basis of qualifications for the performance of TAVR.
The primary objective of this updated document is to promote standards that will help centers achieve high-quality outcomes for patients who have clinically significant aortic valve disease.
Outlined in the following text are the most important new areas of emphasis within the updated document:
• The document focuses on the overall goal of improving patient outcomes at all sites and on providing guidance regarding the use of data and analyses. For example, sites whose risk-adjusted outcomes are worse than expected for their case mix, based on the national benchmark population, should initiate robust performance improvement programs, which are often facilitated by external review and recommendations.
• The writing committee has produced a document that is forward thinking, combining site process and outcome performance metrics that can be updated with data reflecting evolving patient characteristics, changing procedure technologies and techniques, and improving short-term and long-term outcomes. Other structural operator and institutional requirements are not expected to change substantially as they reflect basic infrastructure needs and fundamental clinical skills and experience.
• With over 580 active both TAVR-SAVR sites in the US, most patients now have reasonable geographic access to care. Other barriers to access that relate to broader and many fundamental issues in the U.S. healthcare system cannot be addressed in this document.
• The writing committee does not consider the requirements or recommendations in this document to exceed the capabilities of most centers, currently or with reasonable modifications, and the recommendations or requirements are not meant to exclude existing or future centers.
• TAVR continues to be a dynamic, evolving therapy. The phases of TAVR development and distribution in the U.S. healthcare system as well as the transitions in operator and institutional requirements are presented in Figure 1 . The TVT Registry has gathered data from over 100,000 patients who have received TAVR. These data are now focused in three new directions within the 2018 document: c. Quality outcome measures are reported to sites using the TVT database for TAVR and the STS database for SAVR.
d. Ultimately, the goal is to have similar quality outcome measures for both TAVR and SAVR. For TAVR, this will require the development, validation, and use of additional outcome metrics; for SAVR, long-term outcomes such as 1 year survival and impact on quality of life (QoL) will be required.
e. Over time, volume requirements for TAVR and SAVR will be used primarily to ensure that a program has adequate ongoing volume to provide statistically reliable quality metrics and maintain effective processes of care.
Emphasis on the Care of All Patients with Aortic Valve Disease:
The focus of this document is on treating all patients with aortic valve disease and therefore offering all forms of treatment, including TAVR, SAVR, medical care, and palliative care.
Some sites in the United States offer only SAVR, as discussed subsequently in this document. Of particular concern is how patients at these sites will be informed of their possible eligibility for TAVR. This process of informing patients includes possible referral to TAVR sites for consultation and fully informed SDM. • Figure 2 shows the categorization of sites based on their TAVR volume and risk-adjusted outcome measures, such as the observed-to-expected ratio of an outcome measure (e.g., riskadjusted in-hospital, 30-day, and ultimately, 1-year mortality).
One goal of this 2018 document is to promote the ability of all centers to achieve both adequate volumes and acceptable outcomes (i.e., the upper left quadrant in this schematic).
• Volume: It is anticipated that most low-volume sites will steadily increase their number of procedures due to the approval of moderate-risk patients for TAVR, FDA approval of additional indications for TAVR usage, and ongoing aging of the US population.
• Quality: Preliminary data from a new analysis show that there are many low-volume sites with seemingly acceptable outcomes; however, due to the low number of cases in such sites, the assessment of their outcomes is statistically challenging, resulting in substantial random sampling variation (i.e., wide confidence intervals). The volume-outcome relationship and learning curve shown during the initial US experience in TAVR require updating. Conversely, a few higher-volume sites have suboptimal outcomes-an assessment that is more likely to be statistically valid. Irrespective of volume, sites with unacceptable outcomes are of concern and should immediately take corrective actions to improve their outcomes and processes.
In-depth discussion of the statistical challenge of correctly identifying poorly performing TAVR programs with low annual volumes is presented in Appendix A.
• This document specifies operator and institutional requirements, and recommendations. Requirements are based on best available objective evidence and address issues of critical importance for delivering high-quality care. Recommendations are based on expert opinion and apply to important components of programs.
The characterization of quality using the Donabedian triad of structure, process, and outcomes measures is a reasonable framework for establishing TAVR quality. 5 The 2006 Institute of Medicine report, "Performance Measurement: Accelerating Improvement," provides a framework for translating the need for assessment of performance in health care into measures of quality. 6 The measures are related to the key periods of patient evaluation, procedure performance, FIGURE 1 Evolution of site operator requirements for TAVR. This schematic shows the evolution of TAVR site and operator requirements, starting with the investigative phase, which is followed by three commercial phases. As of 2018, the initial commercial phase has ended and TAVR is now in a steady state in which requirements can now be based predominantly on quality metrics, with volume being used only to demonstrate a program's ability to maintain a reasonable number of cases to measure quality (i.e., as a process metric rather than as a surrogate outcome metric). NCD, national coverage determination; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TVT, transcatheter valve therapies postprocedure care, and assessment of medium-term outcomes. This document incorporates several measures into the proposed site requirements. A public comment period was held to obtain further feedback.
| METHODS
Following reconciliation of all comments and sign-off by the writing committee and oversight task force, this document was approved for publication by the approval bodies of the partnering societies.
| STRUCTURAL PROGRAM REQUIREMENTS
The structural measures of quality include the requirement that operators and institutions have the skills, experience, foundational TAVR and SAVR volume, and facilities that are fundamental to delivering TAVR and SAVR. These quality measures of program structure are outlined in Tables 1 and 2 .
| Procedural volume
There are learning curves associated with TAVR. [7] [8] [9] For instance, nonfemoral TAVR involves an important learning process, with [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] cases needed to reach a plateau for procedure time and device success. 10, 11 Analysis of early STS/ACC TVT Registry data shows that the cumulative TAVR volume-outcome relationship is strong during the learning curve, which is expected given that this is a novel procedure with high risk in an elderly patient population. 12 In their analysis, Carroll et al. 12 noted that there was a steep slope for improved major outcomes in the first 100 cases.
TAVR case-volume requirements listed in this document ensure foundational data minimum needed to maintain program and operator effectiveness and efficiency as well as sufficient sample size for measurement of quality outcomes.
Sites that are not in the higher-volume/experienced tier programs may provide high-quality TAVR care, typically via the wellestablished transfemoral approach. This is especially relevant to the more geographically isolated locations and to underserved patient populations in the US. The 2018 operator and institutional requirements support the ongoing activities of such sites. These programs should have an active quality assessment and improvement process. Higher-risk cases and those requiring more complex access at these low-volume sites should be referred to higher-volume centers 
| Multidisciplinary team
The defining principle of the MDT is an institutionally based joint cardiology and cardiac surgery effort. 13, 14 TAVR programs should only be established if this multidisciplinary partnership is present. Additional providers, including imaging physicians, anesthesiologists, nurses, social services, and administrative support personnel, are also necessary. A comprehensive MDT is mandatory for a TAVR program. 15 The MDT should be supported using institutional resources and consists of physicians and medical personnel from many specialties with specific skills, including:
• Interventional cardiologist.
• Cardiac surgeon.
• Echocardiographic and radiographic image specialist.
• Cardiovascular anesthesiologist.
• Nurse practitioner/physician assistant for preprocedure and periprocedure care and MDT consults.
• TAVR administrative coordinator/program navigator.
• Institutionally supported data manager for STS/ACC TVT registry.
• Hospital administration representative.
Additionally, the following comprise the essential consultative resources for the MDT:
• Electrophysiology capabilities for implantation of permanent pacemakers 24 hr/day, 7 days/week.
• Neurology with a 24-hr/day, 7-day/week stroke team.
• Renal medicine with dialysis capabilities.
• Medical and palliative care for patients who are not TAVR or SAVR candidates.
• Vascular surgery support.
With increasing use of conscious sedation, the perfusion, and operating room (OR) teams will not be necessary in many transfemoral procedures. 16 Additionally, an anesthesiologist may not be present in some instances, depending on patient severity and the training and skillsets of other staff; however, anesthesia and hemodynamic support must nonetheless be readily available.
| Knowledge base and skills
One of the cornerstones of the success of transcatheter valve programs is the partnership between cardiologists and cardiac surgeons, the underlying principle being that no one individual, group, or specialty possesses all of the necessary skills for optimal patient outcomes. 13, 17 The success of these programs depends on a group of professionals, each with his or her own skillset, working together to provide the best possible patient-centered care. 13, 18 There are specific and unique cognitive and technical skills that are essential for all physicians for optimal performance of TAVR irrespective of specialty background. 19, 20 For the purpose of this document, the term "TAVR proceduralist" refers to either interventional cardiologists or cardiac surgeons. These clinicians should possess extensive knowledge of valvular heart disease (VHD), including the natural history of the disease, hemodynamics, appropriate diagnostics, and imaging, optimal medical therapy (particularly of comorbidities), application and outcome for both TAVR and SAVR, procedural and perioperative care, and long-term follow-up. 21 The ability to accurately interpret noninvasive imaging studies during patient evaluation, intraoperatively, in the immediate postoperative period, and at follow-up is critically important. The MDT should have access to expert imaging including echocardiographic interpretation skills for transthoracic and both two-and three-dimensional transesophageal echocardiography studies. Expertise in interpretation of computed tomography (CT) scans, including gated CT angiograms of the heart and iliofemoral vessels, is essential for understanding anatomic issues such as:
• The size, shape, degree, and distribution of calcium in the aortic valve annulus.
• The presence and degree of calcium in the left ventricular (LV) outflow tract and aorta.
• The size and morphology of the sinuses of Valsalva.
• Hypertrophy of the basal septum.
• The location of the coronary arteries.
• Calcification, dilatation, angulation, and tortuosity of the aorta.
• Calcification, tortuosity, and caliber of the iliofemoral and brachiocephalic vessels. 20, 21 There should also be mastery of post-acquisition CT software for detailed analysis of the heart, aorta, and peripheral vessels.
Essential technical skillsets required for the safe and effective performance of TAVR procedures include but are not limited to:
• An understanding of radiation safety, optimal fluoroscopic imaging, and the use of contrast agents.
• The use of hemodynamic monitoring systems.
• Large-bore vascular access and closure techniques.
• Balloon dilatation of the aortic valve.
• Advanced wire skills, including knowledge of the full array of guidewire technologies applicable to TAVR.
• Retrieval devices and techniques.
• Peripheral vascular diagnostic and interventional techniques, including use of covered stents.
• Abdominal and thoracic endovascular aortic repair.
• Coronary diagnostic and interventional techniques.
• Percutaneous LV mechanical support devices.
• Percutaneous closure of paravalvular leaks.
• The ability to rapidly diagnose and treat rhythm disturbances.
• An understanding of the indications for placement of permanent pacemakers in the TAVR setting. A specifically designed hybrid OR interventional suite is ideal;
however, in the absence of such a facility, the interventional car- and clinicians, to provide knowledge regarding aortic valve disease and its treatment; and (2) access to decision aids that allow for assessment of patient-specific risk and benefit for both TAVR and SAVR. 25 Other best practices 7 include offering patients access to their medical records and training clinicians to help patients define their goals and treatment preferences. SDM has been actively promoted by CMS to enhance beneficiary engagement and incentives. 
| MDT patient case conference requirements
The discussion by the MDT should drive the recommended procedure. Accordingly, criteria related to both SAVR and TAVR are addressed in this document. For some patients in whom either therapy is not appropriate, medical or palliative therapy should be offered.
Therefore, programs need to have resources and a process in place that meet the following requirements: This 2018 update addresses the need for a multidisciplinary approach and the importance of patient access, when appropriate, to all treatment options, by requiring that the following be documented:
• One cardiac surgeon (rather than 2) at the TAVR-performing institution, who is part of the MDT, has independently examined the patient face-to-face; evaluated the patient's suitability for SAVR, TAVR, or medical or palliative therapy; and has documented the rationale for their clinical judgment. The rationale and recommendations must be available to the MDT. Documentation from two cardiac surgeons is no longer felt necessary because of the established role of TAVR with published AUC 24 and greater experience in the assessment of risk for SAVR.
• There should also be documentation of an additional physician who has independently examined the patient face-to-face, evaluated the patient's suitability for all forms of valve therapy, and documented the rationale for their clinical judgment. That rationale must be available to the MDT.
• For patients having TAVR, this documentation is typically provided by an interventional cardiologist who is part of the TAVR program, although general cardiologists with an expertise in VHD can provide this documentation.
• For patients having SAVR, this documentation can be provided by a variety of physicians and preferably at least one physician from the MDT; however, the additional physician does not necessarily have to be part of the team as long as he or she is knowledgeable, is well-informed with regard to the current status of all forms of treatment for aortic valve disease, and has knowledge of TAVR. The purpose of this requirement is to emphasize the importance of patients being well-informed Optimal program characteristics include documentation of multidisciplinary approach and patient access to all forms of therapy for aortic valve disease (TAVR, SAVR, and medical therapy) using an SDM process.
• For all patients with aortic stenosis meeting criteria for valve replacement, there should be documentation of the following:
An evaluation completed by both a cardiac surgeon and cardiologist with knowledge and experience in both TAVR and SAVR. Education of patients regarding the treatment recommendations and options. The use of an SDM process incorporating patient preference.
• For patients undergoing TAVR, there should be documentation of an evaluation by one surgeon involved in the TAVR program.
For this requirement to meet CMS coverage criteria, the NCD recommendation of evaluation by two surgeons for all patients having TAVR should be updated.
TAVR volume and quality requirements To have optimal outcomes, a program will have:
• ≥50 cases per year or 100 cases over 2 years.
• Minimum quality requirement: STS/ACC TVT Registry-reported 30-day risk-adjusted all-cause TAVR mortality above the bottom 10% for metrics outlined in Table 1 .
To have optimal outcomes, a program will ensure program directors are responsible for accurately reporting MDT clinical volume and outcomes to the STS/TVT Registry and the STS National Database.
To have optimal outcomes an institution will have the following resources and experience:
• PCI ≥300 PCIs/year. Active participation in the NCDR/Cath PCI Registry or a validated state/multi-institutional consortium that gathers and reports risk-adjusted and benchmarked outcomes. PCI in-hospital risk-adjusted mortality (NQF endorsed) above the bottom 25th percentile for four consecutive quarters.
• Vascular interventions a Experienced and competent physicians in vascular arterial interventions.
• Pacemaker capabilities Experienced and competent physicians for temporary and permanent pacemaker placement and management. On-site services available 24 hr/day and 7 days/week to handle conduction disturbances as a result of TAVR.
SAVR volume and quality requirements To have optimal outcomes a program will have:
• ≥2 hospital-based cardiac surgeons who both spend ≥50% of their time at the hospital with the proposed TAVR program • ≥30 SAVRs per prior year or 60 over 2 years. b
• Quality assessment/quality improvement program: Active participation in STS National Database to monitor outcomes. Quality Metric: STS 2 or 3 star rating for isolated AVR and AVR + CABG in both reporting periods during the most recent reporting year.
To have optimal outcomes, a program will have a quality assessment/quality improvement program that includes:
• Active institutional participation in the STS/ACC TVT Registry and STS National Database or a validated state/multi-institutional consortium registry Registry submission of all commercial cases using FDA-approved TAVR/SAVR technology, including off-label uses. Registry documentation that data submissions meet performance metrics for completeness and accuracy as defined by each registry.
• MDT quarterly meetings, with documentation of the following:
Review of institutional reports for TAVR (quarterly) and SAVR (semiannually) from the STS/ACC TVT Registry or STS National Database or an alternative approved registry. Assessment and proposed actions if site performance for TAVR and SAVR is suboptimal relative to volume and quality requirements, including national benchmarking of performance metrics as outlined in Tables 1 and 2 . Presentation of selected TAVR/SAVR cases at quarterly mortality/morbidity conferences.
• Documentation of incorporation of TAVR/SAVR AUC in the patient selection process. 23 To have optimal outcomes, all MDT members will participate in appropriate CME annually.
Abbreviations: ACC, American College of Cardiology; AUC, appropriate use criteria; EVAR, endovascular aneurysm repair (or endovascular aortic repair); FDA, U.S. food and drug administration; NCD, national coverage decision; NCDR, national cardiovascular data registry; NQF, national quality forum; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TEVAR, thoracic endovascular aortic/aneurysm repair; TVT, transcatheter valve therapies. a Vascular arterial interventions include TEVAR/EVAR, carotid stenting, renal artery stenting, iliac and femoral artery stenting, coarctation stenting, and acute limb ischemia-related interventions. b For the purposes of this hospital volume requirement SAVR is defined to include all aortic valve replacement (mechanical, bioprosthesis, homograft, autograft [Ross], composite valve graft or root replacement) or aortic valve repair procedures, including concomitant valve resuspension for acute aortic dissection and valve-sparing aortic root replacement. Simple adjuvant aortic valve procedures (e.g., suturing closed regurgitant aortic valves in an LVAD patient, excising a papillary fibroelastoma or thrombus, and so on) are not counted.
regarding all treatment options according to their clinical circumstances.
• It is reaffirmed that this direct patient evaluation is optimally performed jointly in a multidisciplinary valve clinic.
• Documentation of a multidisciplinary approach by both a surgeon Operational details
• The MDT should be codirected by an interventional cardiologist and a cardiac surgeon, both of whom are responsible for meeting programmatic quality metrics and credentialing, as outlined in Tables 1-2 , and 4. The MDT, however, goes well beyond this central collaboration and should include key providers from other physician groups (e.g., noninvasive cardiology, palliative care, geriatrics, and critical care medicine) as well as advanced patient practitioners, nurses, research personnel, and administrators. Thus, the MDT must take into account the broad range of resources necessary for a successful multidisciplinary valve therapy program.
• Formal group MDT meetings (distinct from the usual "cardiac catheterization conference") should take place regularly to review all patients referred for procedures, consider patient selection, and discuss morbidity and mortality and long-term outcomes of treated patients. In addition, these formal meetings of the MDT should form the basis for a local "TAVR Steering Committee" that provides oversight and direction for the TAVR program.
• Following the decision that a given patient is an appropriate candidate for TAVR, the procedure must be carefully planned. Cardiac surgical teams are familiar with and routinely use "preprocedure briefings" before complex cardiac surgical operations. In such briefings, immediately prior to the procedure, all team members (i.e., surgeons, anesthesiologists, perfusionists, nurses, and technicians) discuss the intended procedure, including the following:
(1) the steps of the planned procedure; (2) specific tools and equipment needed (beyond those typically used); (3) possible complications that may arise during the procedure; and (4) contingency plans that will be implemented should the unexpected occur. The immediate availability of MDT physician support in emergency decision-making and therapy is essential. It is, therefore, important that the roles of the various specialties be clearly delineated during preprocedure planning.
• Complicated postprocedural courses are common in high-risk patients, who comprise a significant portion of the population treated with TAVR. A team approach in this setting is critical.
Specific and regular in-service educational conferences to impart the necessary familiarity are recommended.
• Long-term follow-up for these patients is imperative. Long-term follow-up planning and resources for this important phase of care are incumbent responsibilities of the MDT and the hospital administration.
• Post-approval registries (e.g., STS/ACC TVT Registry) 28 are required for TAVR. Therefore, a data collection/research unit and staff within the MDT are necessary components that should be funded by the hospital.
• A financial structure that shares physician reimbursement for these procedures is a recommended incentive for collaboration between cardiac surgeons and cardiologists. This important principle will ensure that cardiac surgeons and cardiologists participate jointly in performing procedures and that each patient receives optimal patient-centered treatment.
• It has been demonstrated that a dedicated full-time individual (such as an experienced advanced cardiac nurse specialist serving as clinical coordinator) can be supportive of the efficient operational function of the MDT.
| Patient selection considerations
There are legitimate concerns that many patients with severe AS Frailty, cognition, QoL, immobility, and disability
Arnold et al., 29 using PARTNER (Placement of Aortic Transcatheter Valve) Trial TAVR patients, were the first to compile an analytic risk predictor based on the KCCQ. Poor outcome was defined as death, KCCQ <45, or decrease in KCCQ ≥10. Thirty-five percent of patients had a poor outcome at 6 months (19% dead, 16% alive without functional benefit). 29 Looking at 1-year outcomes after TAVR in three PARTNER sites at which frailty was rigorously assessed, this group used a KCCQ threshold of <60 to predict poor outcome. 30 The frail patients had a 33% mortality rate, compared with 16% for those who
were not deemed frail (P = 0.004). Poor outcome occurred in 50% of the frail subgroup versus 32% of the nonfrail subgroup (P = 0.02). There should be documentation of a multidisciplinary approach and of patient access to all forms of therapy for aortic valve disease (TAVR, SAVR, and palliative) and medical care using an SDM process.
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Completion of an evaluation by both a cardiac surgeon and a cardiologist with knowledge and experience in both TAVR and SAVR. Education of patients regarding the treatment recommendations and options by the multidisciplinary team. Use of an SDM process incorporating patient preference.
• For patients undergoing TAVR, there should be documentation of evaluation by one surgeon involved in the TAVR program.
For this requirement to fulfill CMS coverage criteria, the NCD should be updated as it currently recommends evaluation by two surgeons for all patients having TAVR.
The proposed TAVR proceduralist for a new TAVR program should document the following:
• Prior TAVR experience with participation in 100 transfemoral TAVRs lifetime, including 50 TAVRs as primary operator.
• Being board eligible or certified in either interventional cardiology or cardiothoracic surgery.
• Certification of device-specific training on device(s) to be used.
The TAVR sites must have:
• The site must have documented expertise, state-of the-art technology, and a dedicated board-certified imager that is a member of the MDT.
• Echocardiography: TTE, TEE, and three-dimensional.
• CT scan and MR imaging. The institution should document the following prior to expanding into alternative-access TAVR (e.g., transapical, direct aortic, brachiocephalic arteries, transcaval): • Completion of 80 TAVRs using transfemoral access with an STS/ACC TVT Registry 30-day risk-adjusted TAVR all-cause mortality "as expected" or "better than expected."
The institution should document the following concerning its SAVR program:
• ≥2 hospital-based cardiac surgeons who both spend ≥50% time at the hospital with the proposed TAVR program.
• Minimum hospital SAVR volume a : 40 per prior year or 80 over 2 years.
• Quality assessment/quality improvement program:
Active participation in the STS National Database or a validated state/multi-institutional consortium that gathers and reports risk-adjusted and benchmarked outcomes. Registry submission of all cases using FDA-approved TAVR/SAVR technology, including off-label uses. Registry documentation that data submissions meet performance metrics for completeness and accuracy as defined by each registry.
• Multidisciplinary team quarterly meetings with documentation of the following:
Review of institutional reports for TAVR (quarterly) and SAVR (semiannually) from the STS/ACC TVT Registry and STS National Database or an alternative approved registry. Assessment and proposed actions if site performance for TAVR and SAVR is suboptimal relative to volume and quality requirements, including national benchmarking of performance metrics as outlined in Tables 1 and 2 . Presentation of selected TAVR/SAVR cases at quarterly mortality/morbidity conferences. Documentation of incorporation of TAVR/SAVR AUC into patient selection process. 23 Continuing education requirements:
• It is expected that the MDT will participate in appropriate CME. When the 2011-2014 STS/ACC TVT Registry cohort was analyzed using baseline and 1 year KCCQ, those who initially self-reported very poor health status (KCCQ <25) had a 1 year mortality exceeding 25% after TAVR-more than twice as high as those who felt they had "good" health status at baseline. 32 From these initial reports it is reasonable to conclude the following:
• TAVR is not appropriate for patients who have reached a level of futility (life expectancy despite TAVR of <1 year).
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• TAVR is not appropriate as an end-of-life treatment as it does not help patients and is not sustainable financially for society.
• Real-world application of TAVR is not constrained by the strict exclusion criteria inherent in the controlled trials; thus, sites need to carefully assess their selection criteria and subsequent TAVR outcomes.
• The benefit of TAVR should be defined not only by survival compared with alternative management strategies but also in terms of patient-reported health status, including QoL, freedom from recurrent hospitalization, maintenance of independent living, and functional state at 1 year.
• Procedural denial in elderly patients with multiple medical problems and limited life expectancy should not be misconstrued as a personal defeat.
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• Initial reports studying changes in KCCQ score are useful for defining the impact of TAVR on patient-reported health status.
• The score is not disease specific and is influenced by other conditions that are often present in elderly patients with severe AS.
• These reports included predominantly inoperable and high-risk patients and are not likely to reflect the benefits of TAVR in intermediate-risk patients.
• TAVR procedure and 1-year outcomes have overall improved as these analyses were completed; therefore, these studies need to be updated for contemporary patients undergoing TAVR, as well as SAVR.
• We currently do not have predictive tools that can clearly differentiate between those who will benefit from TAVR and those who will not. It is naïve to expect that predictive "crystal balls" will ever remove uncertainty regarding the outcome of an individual patient, but these tools do allow some empirical evidence to be incorporated into the SDM process:
• Arnold et al. 40 have developed outcome predictive models that need to be used prospectively and validated.
• The thresholds of an acceptable probability of optimal, suboptimal, and poor outcome are somewhat arbitrary.
• Theoretically, determining that a patient is likely to derive no benefit from TAVR is one justification for procedural denial;
this information should be provided to patients and their E166families so that they can exercise individual autonomy. Furthermore, physicians must be responsible stewards of society's limited resources.
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• Procedural denial based on imperfect predicative models and clinical judgment does involve an ethical challenge for clinicians.
• Decision making in patients who may have reduced benefit from TAVR does not necessarily mandate that the MDT team deny treatment; however, it should initiate a more thoughtful discussion with the patient and family before moving forward with TAVR. Utilization of palliative care consultants is helpful.
• Progress has been made in identifying patient characteristics that are statistically associated with markedly limited life expectancy and lower likelihood of functional benefit after TAVR. 45 No single one of these factors clearly supports denial of TAVR as an option, but they inform the decision process and discussion with the patient and family.
• These characteristics include end-stage renal disease or dialysis, [46] [47] [48] [49] [50] advanced lung disease (especially if oxygen dependent), 51, 52 slow ambulation (6 min walk time < 150 m), 51 atrial fibrillation, 46 poor LV systolic function (LV ejection fraction <30%, LV stroke volume index ≤35 mL/m 2 , impaired contractile reserve with dobutamine stress echocardiography), 53 low aortic gradient, 53 pulmonary hypertension, 43, 52 severe organic mitral regurgitation, 54 and STS-Predicted Risk of Mortality (PROM) score > 15%. 36 Advanced dementia and impaired cognitive ability, active cancer, marked musculoskeletal disability, debilitating frailty, and severe cachexia and sarcopenia (low body mass index) are other obvious conditions for which TAVR procedural denial may be appropriate.
Predictive risk models
SDM has also been actively promoted by the professional society guidelines on the management of VHD, incorporating both the MDT approach and the assessment of individualized patient risk that is available for both SAVR and TAVR. The following are recognized risk calculators for each procedure:
• Online STS Adult Cardiac Surgery Risk Calculator.
• an STS-PROM score over 15% who received TAVR did not have any appreciable benefit in all-cause mortality out to 5 years (P = 0.075). 36 It was only with respect to cardiovascular death at 5 years that patients with an STS-PROM score > 15% who received TAVR lived significantly longer (P = 0.01) than did those who received medical therapy. 36 Therefore, when the STS-PROM score exceeds 15%, it is valuable in deciding whether or not TAVR is futile and should be withheld. The achievement of the goals of SDM can be challenging and time-consuming. As pointed out by CMS, "practitioners have found it difficult to integrate SDM into their routine workflows for various reasons such as overworked physicians, insufficient practitioner training, inadequate clinical information systems, lack of consistent methods to measure that SDM is taking place, and uncertainty as to whether, or how, to promote change and invest in the time, tools, and training required to achieve meaningful SDM". and SAVR using quality measures from the STS/ACC TVT Registry. 25 2. An ACC CardioSmart-sponsored initiative directed out of the University of Colorado that features two paper decision aids and web-based videos that address patients at moderate SAVR risk who are making a choice between TAVR and SAVR, 56 and patients considered inoperable who are making a choice between TAVR and medical management. 57 
| SDM requirements

| OUTCOME REQUIREMENTS
The outcome measures of quality and associated requirements are outlined in the accompanying tables. Tables 3 and 4 include outcome measures of quality for PCI and SAVR. Table 1 The STS/ACC TVT Registry has incorporated patient-reported health status using the KCCQ, which has been validated in AS. 59 The derived patient score gives valuable information regarding the patient's status both pre-TAVR and post-TAVR. The baseline score is useful as a prognosis marker, and the change in KCCQ post-TAVR is a marker of whether the patient has derived benefit. 32, 60 Rehospitalization rates are additional measures of outcomes that can be considered to assess broad aspects of care, including patient selection, procedure performance, and postprocedure care. All data used to fulfill the requirements to maintain a safe, efficient, and effective TAVR program are currently generated from the STS/ACC TVT Registry for TAVR and STS National Database for SAVR. These requirements will maintain uniformity, consistency, and quality control for all sites. Individual TAVR site reports are generated quarterly by the STS/ACC TVT Registry. Each metric is accompanied by a national benchmark with a median value and interquartile range analyzed from the previous rolling four quarters of all site data submitted to the registry that pass a data quality check. These national benchmarks are presented graphically using box plots (see Figure 3) .
As shown in Tables 1 and 2 , this method of individual site data presentation is a convenient first step for programs to use as they assess their performance; however, the method has important limitations.
Box and whisker plots only include a site's point estimate and do not provide a measure of the substantial uncertainty associated with small sample sizes. We therefore advocate the use of a widely employed alternative, the funnel plot, as described by Spiegelhalter. 62, 63 This graphical approach has numerous advantages. It explicitly conveys the greater random fluctuation inherent to samples drawn from programs with lower volumes, and can be used with varying upper and lower control limits (e.g., 95% for outlier status, 90% for warning status).
The STS database reports are based on 3 years of data and advance every 6 months. Table 1 shows the current and future primary (i.e., essential) performance metrics necessary for maintenance of both TAVR and SAVR programs. These metrics were chosen by consensus of expert opinion.
The 1 year risk-adjusted mortality rate, composite measures, and patient-reported health status (including QoL, which is part of the KCCQ questionnaire) will be future outcomes metrics to be introduced into the maintenance requirements as the capabilities of the registry. In 2017, the STS/ACC TVT Registry started requiring a KCCQ metric comparing baseline and post-TAVR scores.
Some warning signals for problematic performance are shown in Table 1 and include sites with worse than expected performance for risk-adjusted measures for two consecutive reports, and points falling outside the selected control limits on funnel plots for unadjusted mea- Table 2 is a continuation roadmap for site MDT quality assessment/quality outcomes conferences to regularly review each outcome metric in Tables 1 and 2 , using nationally benchmarked data, and have their data available, when appropriate, for internal and external review. Table 2 also includes other secondary outcome metrics that should be monitored, evaluated, discussed, and compared with TVT Registry-generated benchmarks to enhance the overall performance of a site program.
There are two important considerations in the use of Tables 1   and 2 
| REGISTRY REQUIREMENTS
Measurement of a participating site's quality of care is routinely presented to that site by the quarterly reports in benchmarked format from the STS/ACC TVT Registry. 64 Sites receive reports on the and improve the quality of care at their site. The STS also has extensive knowledge and experience with quality assessment specifically for SAVR. Using the past experience of both of these societies, a similar approach for TAVR will be outlined. 58, 65 The STS uses quality measures to provide members of their national database with a one-star to three-star rating system: three stars indicate the highest performance, whereas one star indicates the lowest performance in SAVR. 58, 65 Centers providing TAVR, as a rapidly evolving therapy, should focus on the use of quality measures for individual site and national quality improvement activities and also for performance assessment, public reporting, and documentation for pay-forperformance.
TAVR is still dynamic and rapidly evolving. Major clinical research issues remain unanswered. Some of the critical unanswered questions for TAVR in 2018 are listed in Table 5 . Submission of data on all commercial TAVR cases to a national registry approved by CMS is an NCD requirement for all TAVR technologies. 27 The STS/ACC TVT Registry (NCT01737528) has been approved by CMS to meet the registry requirements outlined in the NCD for TAVR. 28 This process of ongoing evidence development is a CMS responsibility and is likely to continue as such for additional years. th Percentile -10% of hospitals achieved "better" scores than the 90 th percentile. Your hospital position -"Your Hospital Position" is in relation to all other hospitals' data. The assessment of predicate site quality of care using valid measures and the multifaceted critical uses of performance metrics underscore the need for clinical registries and justify the time and expenses associated with data submission by sites.
In this update on TAVR, there has been an emphasis on the need for programs to monitor the quality of their care for both TAVR and SAVR. The two national registries provide regular reports to all participating sites that include risk-adjustment of key outcomes and national benchmarks that allow a site to compare themselves to others. This document on TAVR operator and institutional requirements also provides a blueprint for sites using these quarterly reports for the MDT to meet, discuss their results, and take actions to improve.
One of the most crucial components of research is complete, accurate, and timely data submission from sites. Industry-sponsored research typically provides funding for data acquisition and follow-up at the site level. Intense monitoring of investigative sites, the use of core laboratories, and adjudication of endpoints are standard best practices in pivotal research studies. The STS/ACC TVT Registry uses site-reported data but without core laboratories and regular Optimizing patient selection and patient-centered outcomes: preprocedure patient characteristics and 1-year outcomes
The benefit of TAVR in terms of survival with improved functional state and patient-reported health status is achieved at 1 year in approximately two-thirds of patients who are inoperable or at high risk for surgery. 59 On average, severe lung disease, undergoing dialysis, and/or very poor baseline health status were associated with lower probability of benefit, but many with these identifiers still benefitted. Can predictive models be developed that would guide patient selection and shared decision-making more accurately?
Best practices in TAVR and SAVR decision-making
The spectrum of patients with severe aortic stenosis is broad and includes those who may not benefit from AVR due to extensive comorbidities, those receiving TAVR who are inoperable or at high risk for SAVR, and those who could undergo TAVR and SAVR at low to intermediate risk.
The optimal process for the making of recommendations by multidisciplinary teams has not been studied, and the incorporation of patient preferences involves a separate process that is not well-described.
Real-world outcomes of TAVR in patients with intermediate surgical risk.
Published trials of intermediate risk were conducted in highly selected sites using inclusion and exclusion criteria. Real-world results from over 500 sites in the United States are likely to have a more diverse patient population. Are outcomes comparable to those noted in clinical trials?
Incidence, timing, predictors, and impact of permanent pacemakers after TAVR using current-generation TAVR technology and implantation techniques.
The need for permanent pacemakers following TAVR remains substantial. Increasingly, patients are discharged within 24-48 hr after discharge, perhaps increasing the occurrence of CHB as an outpatient event that could lead to sudden cardiac death. What is the optimal management to minimize CHB and the best means of identifying those at risk?
TAVR site variations in patient selection, procedure performance, site experience, yearly case volumes, and outcomes
With maturation of TAVR, there is a need to understand variations between hospitals in the type of patients being treated, metrics of site performance, yearly case volume, and use of multiple different TAVR technologies
Long-term durability of bioprosthetic TAVR and SAVR valves for both native aortic valve disease and treatment of degenerated SAVR valves
As more patients are treated, the burden of comorbid conditions are lowered. It is expected that their increased survival of 5-10 years post-TAVR will provide the opportunity to assess the incidence, frequency, and associated factors leading to structural valve deterioration
Frequency of leaflet thrombosis of tissue valves, time of onset, association with clinical events, modification with anticoagulation, and optimal duration of anticoagulation Recent data show leaflet thrombosis occurs in 13% of TAVR bioprosthetic valves and 4% of SAVR bioprosthetic valves. 66 The median time from SAVR to CT scanning was 163 days (IQR: 79-417 days), and from TAVR to CT scanning, 58 days (IQR: 32-236 days). Warfarin and DOACs were effective in preventing and resolving leaflet thrombus. Leaflet thrombus was associated with TIA and increased TAVR valve pressure gradients Abbreviations: CHB, complete heart block; CT, computed tomography; DOAC, direct oral anticoagulant; IQR, interquartile range; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack. 
monitoring. The STS/ACC TVT
Registry, via the Duke Clinical Research Institute, does adjudicate several key outcomes for TAVR.
| Requirements and recommendations for new TAVR programs
Because TAVR is now a widely available and standard form of therapy, an institution should not initiate a TAVR program with a completely inexperienced MDT. New programs should have in place processes for optimizing treatment selection and SDM, as outlined in the previous text. The specific requirements for a new TAVR program (Table 4) , encompassing issues such as TAVR-specific experience and training, are as follows: Individual Site Requirement: Each site within a hospital system should meet the minimum procedural volume, TVT Registry, and TAVR personnel requirements to be eligible to become an active TAVR program. Also, each site within a system should have proceduralists and surgeons who spend at least 50% of their active practice time at that particular site and meet the minimum requirements of procedures for eligibility at that site to become a program. There will be no blanket eligibility for additional sites within a system based on the fact that one site within that system met eligibility requirements.
| Requirements and recommendations for existing TAVR programs
There will be a 2 year period to allow new programs to "bridge," grow, Many studies have demonstrated a volume-outcomes relationship for SAVR, [93] [94] [95] [96] [97] [98] as is the case for many other procedures. 99 Birkmeyer et al. 99 demonstrated an almost 30% lower mortality rate Recently, the use of high-pressure balloons to fracture failed surgical implants to facilitate larger TAVR implants has been described. 107, 108 The ViV option has important implications for planning the initial implant, including favoring larger prostheses to minimize the anticipated gradient after ViV deployment. A controversial question concerns the advisability of adding aortic root enlargement to accomplish this aim, although evidence suggests there is no increased operative risk in experienced hands. 109 The ViV consideration may also favor stented over stentless xenograft procedures. over half at no increased risk of stroke. 112 A reduction in bleeding events without increase in thromboembolism has also been demonstrated when telemedicine-guided anticoagulation with home testing is employed. 113 Use of these new-generation mechanical valves with home international normalized ratio testing has shown bleeding and thromboembolism rates comparable to tissue prostheses and suggests a mortality benefit at 7.5 years for mechanical valves over tissue in patients younger than age 65 years. 114 The role of aortic valve repair procedures continues to be explored, offering hope for a solution free of "prosthetic valve disease," with its risks of thrombosis, bleeding, infection, and structural deterioration. 115 Valve-sparing and preserving interventions on the aortic root are also gaining wider application as an alternative to composite root replacement. 116 
| SAVR-only programs
In an effort to attain equivalence for the care of patients with aortic valve disease at all institutions, emphasis at SAVR-only sites must be placed on the larger context and specifically on the broader goal of E174optimizing patient care. Therefore, programs that offer SAVR only should have the resources and processes in place to ensure adherence to the following recommendations:
1. Presence of an MDT. The rationale for this is that no one individual, group, or specialty possesses all the necessary skills for optimal patient outcomes 13, 17 and that the success of these programs depends on a group of professionals working together, each with his or her own skillset, to provide the best possible patientcentered care. The MDT is an essential requirement. • Produce an annual report using adjusted outcomes based on stable and well-validated statistical models that is available, published in professional journals, provided to CMS, and contains the following summary statistics:
• Number of all active TAVR sites and frequency distribution of yearly site volume. The report should identify the number and percentage of active TAVR sites whose yearly volume falls below the minimum requirements outlined in this document.
• Number of all active SAVR sites and frequency distribution of are not counted.
• Number of active TAVR sites that both meet and fail to meet the data quality and completeness requirements of the STS/ACC TVT Registry.
• Number of active SAVR sites that both meet and fail to meet the data quality and completeness requirements of the STS National Database.
• Number of TAVR sites that meet and fail to meet the outcomes standards outlined in Table 1 .
• Number of SAVR sites that achieve each category of star rating.
• TAVR and SAVR sites that fail to meet volume, quality of care, and compliance for reporting performance metrics as outlined in this document should receive a letter from the relevant national registry informing them of this finding.
• Professional societies should consider means of helping sites and physicians who are failing to meet the quality of care and compliance for reporting performance metrics for TAVR and SAVR.
Professional societies should work with all stakeholders to ensure recommendations are met in a manner that ensures quality care.
| CONCLUSION
TAVR has matured as a therapeutic option for patients requiring AVR.
In the prior 2012 document, 1 the operator requirements were based on skills that would be necessary to perform TAVR. At this time, it is felt that such skills are best learned by doing TAVR. Therefore, Because TAVR is an evolving form of treatment impacted by continual improvement in advanced devices and simplification of procedures, the outcome thresholds for quality of care will be moving targets.
Therefore, the mechanism of data presentation and interpretation will be determined using risk-adjusted individual and composite outcomes based on the accumulation of data through the four most current rolling quarters of data, presented in a variety of formats including box and whisker plots (which do not account for random sampling variation, especially at lower volume programs), funnel plots (which visually demonstrate sampling variation at low volumes, and accom- To help mitigate the statistical challenges of evaluating lowvolume programs, a 3-year rolling data time frame is recommended to provide more observations and to better assess true differences in outcomes. In the future, composite, multidimensional performance measures will further increase the effective number of endpoints.
Consistent with standard profiling practice, the committee recommends identifying true quality outliers as having risk-adjusted performance that is statistically significantly different than expected for their case mix, based on the overall performance of the benchmark population of providers for similar patients. Statistical significance is usually determined by assessing whether the 95% confidence intervals around the provider's point estimate of risk-adjusted mortality include the overall average mortality, or whether the confidence intervals around their ratio of observed to expected mortality include unity (one). Low-volume centers, particularly newer programs with less than 3 years of rolling data, need to be vigilant in their own internal assessments if "signals" or "trends" for poor quality are appreciated despite not reaching a 95% confidence level due to the challenge of accurate assessment of low-volume center quality.
To provide larger sample sizes and greater statistical power, there will be a 2-year grace period for new sites to accumulate a sufficient number of cases before full accountability of outcomes is required.
Prior to the completion of the 2-year grace period, worrisome trends composite outcomes. For risk-adjusted outcomes or funnel plots, less restrictive confidence intervals or control limits (e.g., 90%) may be used as warning signals that warrant internal investigation and performance improvement, whereas 95% intervals or control limits may be used to more confidently identify outliers. In the latter case, the institution should sponsor an external review to assess the program and make performance improvement recommendations.
